KR100979882B1 - Compositions for preventing and curing diabetes comprising extracts of Lonicera japonica and Panax ginseng C.A. Meyer - Google Patents
Compositions for preventing and curing diabetes comprising extracts of Lonicera japonica and Panax ginseng C.A. Meyer Download PDFInfo
- Publication number
- KR100979882B1 KR100979882B1 KR1020080050372A KR20080050372A KR100979882B1 KR 100979882 B1 KR100979882 B1 KR 100979882B1 KR 1020080050372 A KR1020080050372 A KR 1020080050372A KR 20080050372 A KR20080050372 A KR 20080050372A KR 100979882 B1 KR100979882 B1 KR 100979882B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- gold
- silver
- red ginseng
- diabetes
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 70
- 235000002789 Panax ginseng Nutrition 0.000 title claims abstract description 39
- 239000000203 mixture Substances 0.000 title claims abstract description 31
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 21
- 235000008434 ginseng Nutrition 0.000 title abstract description 7
- 240000004371 Panax ginseng Species 0.000 title description 6
- 244000167230 Lonicera japonica Species 0.000 title description 2
- 235000017617 Lonicera japonica Nutrition 0.000 title description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims abstract description 25
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims abstract description 25
- 229910052737 gold Inorganic materials 0.000 claims abstract description 25
- 239000010931 gold Substances 0.000 claims abstract description 25
- 229910052709 silver Inorganic materials 0.000 claims abstract description 25
- 239000004332 silver Substances 0.000 claims abstract description 25
- 239000004480 active ingredient Substances 0.000 claims abstract description 11
- 235000020710 ginseng extract Nutrition 0.000 claims abstract description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 21
- 235000013376 functional food Nutrition 0.000 claims description 7
- 230000036541 health Effects 0.000 claims description 5
- 235000000346 sugar Nutrition 0.000 abstract description 17
- 238000010521 absorption reaction Methods 0.000 abstract description 12
- PQTCMBYFWMFIGM-UHFFFAOYSA-N gold silver Chemical compound [Ag].[Au] PQTCMBYFWMFIGM-UHFFFAOYSA-N 0.000 abstract description 12
- 239000008280 blood Substances 0.000 abstract description 11
- 210000004369 blood Anatomy 0.000 abstract description 11
- 230000003178 anti-diabetic effect Effects 0.000 abstract description 7
- 230000002401 inhibitory effect Effects 0.000 abstract description 7
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 abstract description 6
- 235000003140 Panax quinquefolius Nutrition 0.000 abstract description 6
- 239000003472 antidiabetic agent Substances 0.000 abstract description 5
- 239000000463 material Substances 0.000 abstract description 5
- 230000002265 prevention Effects 0.000 abstract description 4
- 230000002195 synergetic effect Effects 0.000 abstract description 4
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 241000208340 Araliaceae Species 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- 239000008103 glucose Substances 0.000 description 9
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 229910000898 sterling silver Inorganic materials 0.000 description 5
- 239000010934 sterling silver Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 238000007446 glucose tolerance test Methods 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 229930003471 Vitamin B2 Natural products 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 235000019164 vitamin B2 Nutrition 0.000 description 2
- 239000011716 vitamin B2 Substances 0.000 description 2
- 235000019158 vitamin B6 Nutrition 0.000 description 2
- 239000011726 vitamin B6 Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010061666 Autonomic neuropathy Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000001164 bioregulatory effect Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000000321 herbal drug Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Botany (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
본 발명은 금은화 추출물과 홍삼 추출물을 함유하는 당뇨병 예방 및 치료용 조성물에 관한 것으로, 더욱 구체적으로 금은화와 홍삼을 주정으로 추출한 추출물을 유효성분으로 함유하여 당 흡수를 억제함으로서 혈당 저하를 통한 당뇨병 예방 및 치료 효과를 갖는 조성물에 관한 것이다.The present invention relates to a composition for the prevention and treatment of diabetes mellitus extract and extract containing red ginseng extract, more specifically preventing the absorption of diabetes by lowering blood sugar by inhibiting the absorption of sugar by containing the extract extracted with gold silver and red ginseng as an active ingredient It relates to a composition having a therapeutic effect.
본 발명에 따르면, 금은화 추출물과 홍삼 추출물은 각각 당 흡수를 효과적으로 억제하여 당뇨병에 효과적으로 사용될 수 있음을 확인하였다. 또한 이들 금은화 추출물과 홍삼 추출물을 이용한 혼합 조성물의 경우 금은화 추출물과 홍삼 추출물을 각각 단독으로 투여하였을 때와 비교할 때 현저한 상승효과가 있음을 확인하였고, 이에 따라 항 당뇨 소재로서 이용될 수 있음을 보여주고 있다.According to the present invention, it was confirmed that the gold and silver ginseng extract and red ginseng extract can be effectively used for diabetes by inhibiting sugar absorption, respectively. In addition, it was confirmed that the mixed composition using the gold and silver ginseng extract and red ginseng extract has a significant synergistic effect compared with the administration of the gold and silver ginseng extract alone, and thus can be used as an antidiabetic material. have.
금은화, 홍삼, 추출물, 항 당뇨, 당뇨병 Gold, silver ginseng, extract, anti-diabetic, diabetes
Description
본 발명은 금은화 추출물과 홍삼 추출물을 함유하는 당뇨병 예방 및 치료용 조성물에 관한 것으로, 더욱 구체적으로 금은화와 홍삼을 주정으로 추출한 추출물을 유효성분으로 함유하여 당 흡수를 억제함으로서 혈당 저하를 통한 당뇨병 예방 및 치료 효과를 갖는 조성물에 관한 것이다.The present invention relates to a composition for the prevention and treatment of diabetes mellitus extract and extract containing red ginseng extract, more specifically preventing the absorption of diabetes by lowering blood sugar by inhibiting the absorption of sugar by containing the extract extracted with gold silver and red ginseng as an active ingredient It relates to a composition having a therapeutic effect.
당뇨병은 인슐린의 결핍이나 인슐린 저항성에서 기인되는 당대사에 이상이 발생하는 대사성 질환이다. 당뇨병이 수년간 지속되면 녹내장, 시력상실, 자율신경장애, 신부전, 협심증, 심근경색증, 고혈압, 뇌졸중 등의 합병증을 유발할 수도 있다. 당뇨병에는 인슐린을 분비하는 췌장의 베타 세포가 파괴되어 당뇨가 유발되는 인슐린 의존형 즉, 제 1형 당뇨가 있고 베타 세포는 정상이나 인슐린 리셉터의 저항성에서 유발되는 인슐린 비의존형 즉, 제 2형 당뇨가 있고, 효율적인 인슐린 분 비가 이루어지지 못하는 당내성 이상, 임신성 당뇨병 등이 있다. 현대 사회에서 식습관의 변화로 인한 비만이 급격히 상승하였고, 비만으로 인한 인슐린의 저항성으로 제 2형 당뇨 환자들이 급증하였다. 따라서 부작용이 없고 제 1형과 제 2형 당뇨 모두에 효과적인 소재를 찾기 위해 식물 소재 중 당 흡수를 효과적으로 억제하는 소재를 탐색하였다.Diabetes is a metabolic disease that causes abnormalities in glucose metabolism due to insulin deficiency or insulin resistance. If diabetes lasts for many years, it can cause complications such as glaucoma, blindness, autonomic neuropathy, kidney failure, angina pectoris, myocardial infarction, high blood pressure and stroke. Diabetes has insulin-dependent, type 1 diabetes, in which the beta cells of the pancreas that secrete insulin are destroyed, leading to diabetes, and beta cells have insulin-independent, type 2 diabetes, which is caused by normal or insulin receptor resistance. , Glucose tolerance, and gestational diabetes, which are inefficient insulin secretion. In modern society, obesity due to changes in eating habits has risen sharply, and type 2 diabetes patients have increased rapidly due to insulin resistance due to obesity. Therefore, in order to find an effective material for both type 1 and type 2 diabetes, we searched for a material that effectively suppresses the absorption of sugar in plant material.
본 발명에서 사용된 금은화는 인동초(Lonicera japonica)의 꽃으로 해열작용과 해독작용이 있어 각종 종기와 발열질환 등에 사용되며 약효, 약리적인 효능에 의해 주로 약재로 사용되어온 식물이다. 인동초는 전국 각지의 숲 가장자리를 비롯한 산과 들에서 흔히 자라고 있는 넝쿨나무이며 추운 겨울에도 견뎌 내는 인동과의 반상록 넝쿨 식물이다.Gold and silver coins used in the present invention is a flower of Indongcho ( Lonicera japonica ) has an antipyretic action and detoxification effect is used for various boils and fever diseases, etc. The plant has been used mainly as a medicine by medicinal effects, pharmacological effects. Indongcho is a vine that grows frequently in the mountains and fields, including forest edges around the country, and is a semi-hepatic vine plant of Indongaceae that survives cold winters.
한편, 현대인의 가장 큰 문제점은 비만으로 인한 당뇨병 등의 질병이며, 이 질병을 예방 또는 치료하기 위해서는 탄수화물을 먹었을 때 소장에서 탄수화물과 상경적으로 작용 흡수를 억제하는 것이 가장 이상적이다. 우리나라에서는 동고자 또는 홍삼 등과 같은 엑기스만이 기능성 식품으로 판매가 되고 있으나, 단일 생약제 사용함으로써 단일 생약제에 의한 특정 기능만을 기대할 수 있을 뿐 만 아니라, 단일 생약제가 가질 수 있는 단점을 보안할 수 없는 단점이 있었다.On the other hand, the biggest problem of the modern man is a disease such as diabetes due to obesity, and in order to prevent or treat this disease, it is most ideal to suppress the absorption of the carbohydrates and the carbohydrates in the small intestine when eating carbohydrates. In Korea, only extracts such as bundling or red ginseng are sold as functional foods.However, by using a single herbal medicine, not only can you expect a certain function by a single herbal medicine, but also you cannot secure the disadvantages of a single herbal medicine. there was.
이에, 본 발명자들은 상기 종래기술들의 문제점들을 극복하기 위하여 예의 연구노력한 결과, 금은화의 추출물이 효과적으로 당 흡수를 억제함을 확인하였으며, 특히 홍삼 추출물과의 혼합물에서 상승효과가 뛰어남을 확인하고, 본 발명을 완성하게 되었다.Accordingly, the present inventors have made intensive research to overcome the problems of the prior art, it was confirmed that the extract of gold and silver coins effectively inhibit the absorption of sugar, in particular, the synergistic effect in the mixture with the red ginseng extract, and the present invention To complete.
따라서, 본 발명의 주된 목적은 금은화와 홍삼을 주정으로 추출한 추출물을 유효성분으로 함유하여 당 흡수를 억제함으로서 당뇨병 예방 및 치료 효과를 갖는 조성물을 제공하는 데 있다.Therefore, the main object of the present invention is to provide a composition having the effect of preventing and treating diabetes by inhibiting the absorption of sugar by containing the extract extracted gold and silver ginseng as alcohol as an active ingredient.
본 발명의 한 양태에 따르면, 본 발명은 금은화 추출물과 홍삼 추출물을 유효성분으로 함유하는 혈당 저하를 통한 당뇨병 예방 및 치료용 조성물을 제공한다.According to an aspect of the present invention, the present invention provides a composition for preventing and treating diabetes through lowering blood sugar, which contains a gold and silver extract as an active ingredient.
기존의 항 당뇨에 대한 연구들에서, 금은화가 수십여 가지의 생약과 함께 항당뇨 효능이 있다는 것은 알려져 있고 (예를 들어, 대한민국 공개특허 10-2005-0028272; 다이어트, 항 당뇨, 고지혈증 및 항산화에 효과가 있는 복합처방을 이용한 기능성 식품), 금은화 추출물 단독으로 당뇨 치료활성을 갖는 조성물에 대한 국내특허(공개특허 10-2005-0005630)가 있을 뿐이다. 이에 본 발명자들은 금은화 추출물, 홍삼 추출물, 그리고 이들의 혼합물을 이용한 당내성 시험을 통하여 당 흡수 저해 효과가 있음을 확인하였고, 특히 금은화 추출물과 홍삼 추출물을 단독으로 투여할 때 보다 이들의 혼합물을 투여할 때 더 상승적으로 혈중 당 농도를 저하시킬 수 있다는 것을 본 발명자들이 처음으로 연구하여 그 효과를 확인하였다.In existing studies of anti-diabetic, it is known that gold and silver coins have anti-diabetic effects with dozens of herbal drugs (for example, Korean Patent Publication No. 10-2005-0028272; diet, anti-diabetic, hyperlipidemia and antioxidants). There is only a domestic patent (Publication Patent No. 10-2005-0005630) for a composition having a therapeutic effect on diabetes alone with a functional food using an effective complex prescription) and a sterling extract alone. Therefore, the present inventors have confirmed that the sugar absorption inhibitory effect by using the gold silver extract, red ginseng extract, and mixtures thereof, and in particular, when administering the mixture of gold silver extract and red ginseng extract alone. When the inventors first studied that the blood sugar concentration can be lowered more synergistically, the inventors confirmed the effect.
본 발명의 조성물에서, 상기 금은화 추출물과 홍삼 추출물의 혼합비는 바람직하게는 1:2 내지 2:1 중량비이며, 더욱 바람직하게는 1:1 중량비이다. 본 발명의 실시예와 도 1에서와 볼 수 있듯이, 본 발명의 금은화 추출물은 농도 의존적으로 혈중 당 농도를 저하시킬 수 있으나, 금은화 추출물 단독 사용보다 홍삼 추출물과 1:1 중량비로 혼합한 혼합물이 더욱 효과적으로 혈당 수치를 낮출 수 있음을 확인하였다(표 2 참조).In the composition of the present invention, the mixing ratio of the sterling silver extract and the red ginseng extract is preferably 1: 2 to 2: 1 weight ratio, more preferably 1: 1 weight ratio. As can be seen from the embodiment of the present invention and Figure 1, the gold and silver extract of the present invention can lower the blood sugar concentration in a concentration-dependent manner, the mixture of red ginseng extract and 1: 1 weight ratio is more than using the gold and silver extract alone It was confirmed that blood sugar levels can be effectively lowered (see Table 2).
본 발명의 조성물에서, 상기 금은화와 홍삼은 물, 탄소수 1 내지 4의 저급알코올 또는 이들의 혼합용매로도 추출될 수 있으나, 바람직하게는 에탄올(주정)을 30-90%로 물에 희석하여 추출하는 것이 적당하다. 본 명세서에서 사용된 용어, 주정은 당업계에서 사용하는 용어로서 식용 가능한 에탄올을 의미한다.In the composition of the present invention, the sterling silver and red ginseng may be extracted with water, a lower alcohol having 1 to 4 carbon atoms or a mixed solvent thereof, preferably ethanol (alcohol) is extracted by diluting in water to 30-90% It is suitable to do. As used herein, the term alcohol refers to edible ethanol as used in the art.
상기 주정을 이용한 추출은 일반적으로 식물체에서 생리활성 물질 추출에 가장 많이 사용하는 용매로서, 다양한 성분의 추출에 용이할 뿐만 아니라, 추출 후 분리 정제 시 편리하다. 또한 주정 추출물은 바로 농축하여, 동결건조를 하면 식물체의 추출 건조 분말을 얻을 수 있다.Extraction using the spirit is generally the most commonly used solvent for the extraction of physiologically active substances in plants, as well as easy to extract a variety of components, it is convenient for separation and purification after extraction. In addition, the alcohol extract is concentrated immediately, and lyophilized to obtain an extract dried powder of the plant.
본 발명의 추출물들은 추출하는 구체적인 방법으로, 우선 금은화 추출물은 30-70% 주정으로 2-6시간 동안 추출하는 것이 바람직하고 40-60% 주정으로 3-5시간 동안 추출하는 것이 더욱 바람직하다. 또한, 홍삼 추출물은 30-70% 주정으로 6-10시간 동안 추출하는 것이 바람직하고 40-60% 주정으로 7-9시간 동안 추출하는 것이 더욱 바람직하다. 추출시간은 상기 범위 보다 적을 경우 당 흡수 저해 효과가 있는 활성성분들이 제대로 추출되지 못하게 되고, 반대로 추출시간이 상기 범위 보다 많을 경우 활성성분의 추출 수율이 더 이상 증가하지 않아 생산 공정상 경제성이 떨어지게 된다.As a specific method of extracting the extracts of the present invention, first, the gold and silver extract is preferably extracted for 2-6 hours with 30-70% alcohol and more preferably for 3-5 hours with 40-60% alcohol. In addition, the red ginseng extract is preferably extracted for 6-10 hours with 30-70% alcohol and more preferably for 7-9 hours with 40-60% alcohol. If the extraction time is less than the above range, the active ingredient having a sugar absorption inhibiting effect may not be properly extracted. On the contrary, if the extraction time is more than the above range, the extraction yield of the active ingredient does not increase any more, resulting in inferior economic efficiency in the production process. .
본 발명에서, 상기 조성물이 약제학적 조성물로 이용되기 위해서는 약제학적 분야에서 공지된 방법에 의해 제조될 수 있으며, 그 자체 또는 약학적으로 허용되는 담체, 부형제, 희석제 등과 혼합하여 분말, 과립, 정제, 캡슐제 또는 주사제 등의 제형으로 제조되어 사용될 수 있다. 또한 이들은 경구 또는 비경구로 투여될 수 있다.In the present invention, the composition may be prepared by a method known in the pharmaceutical field to be used as a pharmaceutical composition, and may be mixed with itself or a pharmaceutically acceptable carrier, excipient, diluent, etc. to powder, granule, tablet, It may be prepared and used in formulations such as capsules or injections. They can also be administered orally or parenterally.
본 발명에 따른 금은화 추출물과 홍삼 추출물의 혼합물을 유효성분으로서 투여하는 투여량은 환자의 연령, 성별, 상태, 질병의 증상에 따라 적절히 선택될 수 있으며, 바람직하게는 1일 0.1 내지 1000 mg/kg(체중)의 혼합물이 투여될 수 있다.The dosage for administering the mixture of the sterling silver extract and the red ginseng extract according to the present invention as an active ingredient may be appropriately selected according to the age, sex, condition and symptoms of the disease of the patient, preferably 0.1 to 1000 mg / kg per day. Mixtures of (body weight) may be administered.
본 발명의 다른 양태에 따르면, 본 발명은 금은화 추출물과 홍삼 추출물을 유효성분으로 함유하는 당뇨병 예방 및 치료용 건강기능식품을 제공한다.According to another aspect of the present invention, the present invention provides a dietary supplement for preventing and treating diabetes, which contains a sterling extract and a red ginseng extract as active ingredients.
본 발명에서, ‘건강기능식품’이란 질병의 예방 및 치료, 생체방어, 면역, 병후의 회복, 노화 억제 등 생체조절기능을 가지는 식품을 말하는 것으로, 장기적으로 복용하였을 때 인체에 무해하여야 한다.In the present invention, "health functional food" refers to a food having a bioregulatory function, such as prevention and treatment of diseases, biological defense, immunity, recovery of symptoms, inhibition of aging, and should be harmless to the human body when taken in the long term.
본 발명의 금은화 추출물과 홍삼 추출물이 상기와 같은 당뇨병 예방 및 치료를 위한 건강기능식품으로 이용되기 위해서는, 식품학 또는 약제학적 분야에서 공지된 다양한 방법에 의해 제조될 수 있으며 그 자체 또는 식품학적으로 허용되는 담체, 부형제, 희석제 등과 혼합하여 경구로 섭취할 수 있는 어떤 식품 형태로도 제조될 수 있다. 바람직하게는 음료, 환, 과립, 정제 또는 캅셀 형태이다.In order to be used as a dietary supplement for the prevention and treatment of diabetes mellitus extract and red ginseng extract of the present invention, it can be prepared by a variety of methods known in the food science or pharmaceutical field, or is acceptable It can be prepared in any food form which can be ingested orally by mixing with a carrier, excipient, diluent, and the like. Preferably in the form of beverages, pills, granules, tablets or capsules.
본 발명의 건강기능식품은, 식품 제조 시에 통상적으로 첨가되고 식품학적으로 허용되는 식품보조첨가제를 더 포함할 수 있다. 예컨대, 음료수로 제조되는 경 우에는 본 발명의 식물 추출물 이외에 구연산, 액상과당, 설탕, 포도당, 초산, 사과산, 과즙 등에서 하나 이상의 성분을 추가로 포함시킬 수 있다.The health functional food of the present invention may further include food supplements which are commonly added in food production and are food acceptable. For example, when the beverage is prepared, in addition to the plant extract of the present invention, citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, fruit juice, and the like may be further included.
본 발명에 따른 건강기능식품의 유효성분으로 포함될 수 있는 양은 당뇨병 예방 및 치료를 원하는 사람의 연령, 성별, 체중, 상태, 질병의 증상에 따라 적절히 선택될 수 있으며, 바람직하게는 성인기준 1일 0.01g 내지 10.0g로 포함되는 것이 좋으며, 이러한 함량을 갖는 건강기능식품을 섭취함으로써 항 당뇨 효과를 얻을 수 있다.The amount that can be included as an active ingredient of the health functional food according to the present invention may be appropriately selected according to the age, sex, weight, condition, symptoms of the disease of the person who wants to prevent and treat diabetes, preferably 0.01 days per adult It is good to include from g to 10.0g, by ingesting a health functional food having such a content can be obtained anti-diabetic effect.
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하기로 한다. 이들 실시예는 단지 본 발명을 예시하기 위한 것이므로, 본 발명의 범위가 이들 실시예에 의해 제한되는 것으로 해석되지는 않는다.Hereinafter, the present invention will be described in more detail with reference to Examples. These embodiments are only for illustrating the present invention, and thus the scope of the present invention is not construed as being limited by these embodiments.
실시예 1. 금은화 추출물의 제조Example 1 Preparation of Gold Coin Extract
금은화 500g (건조 중량; 대전약제시장에서 구입한 일광건조된 금은화)을 6L의 50% 주정으로 65℃에서 4시간 동안 1, 2차에 걸쳐 추출하고, 5,000 rpm에서 20분 동안 원심분리한 다음, 감압농축하여 190.3g의 엑기스를 얻었다. 이 엑기스를 금은화 추출물 시료로 하였으며, 이때 수분함량은 32.2%였다.500 g of gold and silver coins (dry weight; sun dried gold and silver coins purchased from Daejeon Pharmaceutical Market) were extracted in
실시예 2. 홍삼 추출물의 제조Example 2. Preparation of Red Ginseng Extract
원료 홍삼(잡삼 또는 중미삼; 한국인삼공사)에 50% 주정을 원료홍삼의 5-6배수 첨가하여 약 60-70℃에서 8시간 동안 추출한다. 추출액을 냉각시킨 다음, 여과하여 슬러지를 제거한다. 이 여과액을 62-74°Bx(이 단위는 당도를 나타내며, 여과액을 62-74°Bx가 될 때까지 농축하여 제조한다)(수분함량 43%)의 잡삼(중미삼) 주정엑기스를 제조하였다. 이 엑기스를 홍삼 추출물 시료로 하였다.50% alcohol is added to raw red ginseng (jasam ginseng or Jungmi ginseng; Korea Ginseng Corporation) 5-6 times the raw red ginseng and extracted for 8 hours at about 60-70 ℃. The extract is cooled and then filtered to remove sludge. This filtrate was prepared by concentration of 62-74 ° Bx (this unit represents sugar, and the filtrate was concentrated until it reached 62-74 ° Bx) (43% of water content). It was. This extract was used as a sample of red ginseng extract.
실시예 3. 금은화와 홍삼 혼합물의 제조Example 3. Preparation of Gold Silver and Red Ginseng Mixture
상기 실시예 1, 2에서 제조한 추출물 시료들을 이용하여 각각 1:1(중량비)로 혼합하여 금은화 추출물과 홍삼 추출물의 혼합시료를 제조하였다.Using the extract samples prepared in Examples 1 and 2 were mixed in a 1: 1 (weight ratio), respectively, to prepare a mixed sample of the gold and silver extract and red ginseng extract.
실시예 4. 금은화, 홍삼 단독 추출물과 혼합물의 당내성 시험Example 4 Glucose Tolerance Test of Gold Silver and Red Ginseng Extract and Mixture
실험동물은 SD(Sprague-Dawley) 래트 (220-250g, 7주령. 코아텍(주)) 수컷을 사용하였으며, 시험군은 상기 실시예 1, 2 및 3에서 제조된 시료들을 생리식염수 0.8ml에 각각 25mg(100mg/체중kg)씩 녹이거나, 실시예 1에서 제조된 시료를 생리식염수 0.8ml에 125mg(500mg/체중kg)을 녹여, 하기 표 1과 같이 사용하였다.The experimental animals were SD (Sprague-Dawley) rats (220-250g, 7 weeks old, KOATEC Co., Ltd.) male, the test group to the samples prepared in Examples 1, 2 and 3 in 0.8ml physiological saline Each 25 mg (100 mg / kg body weight) was dissolved, or 125 mg (500 mg / kg body weight) was dissolved in 0.8 ml of saline solution was prepared in Example 1, was used as shown in Table 1.
[표 1] 당내성 시험을 위한 시험군 및 시료 투여량Table 1 Test group and sample dose for glucose tolerance test
실험시작 전, 24시간 동안 절식시키고 시료들을 먼저 경구로 선투여하고, 10분후 글루코오스(0.5 mg)와 시료들을 혼합하여 동시투여 하였다. 대조군은 물을 0.8 ml 투여하였고 글루코오스는 2 mg/kg이 되도록 시료와 혼합하여 투여하였다. 이 때 투여 volume은 0.8ml로 동일하였다. 글루코오스와 시료의 동시 투여 후, 꼬리 정맥으로부터 채혈하여 0, 30, 60, 90, 120분에 혈당을 측정하였다(도 1과 2).Before the start of the experiment, fasted for 24 hours, and the samples were first orally pre-administered, and after 10 minutes, the mixture was co-administered with glucose (0.5 mg). The control group was administered with 0.8 ml of water and glucose was mixed with the sample to be 2 mg / kg. At this time, the administration volume was the same as 0.8ml. After simultaneous administration of glucose and sample, blood was collected from the tail vein and blood glucose was measured at 0, 30, 60, 90, and 120 minutes (FIGS. 1 and 2).
도 1과 2에서, 금은화 추출물은 농도 의존적으로 혈중 당 농도를 저하시켰다. 특히 500mg/kg에서는 30분과 60분에 각각 22.5%, 24.5%씩 혈중 당 농도를 저하시켰다. 또한, 금은화 추출물과 홍삼 추출물을 각각, 그리고 1:1(중량비)로 혼합한 시료를 100mg/kg으로 투여한 결과, 60분에서 홍삼과 금은화를 각각 투여 했을 때는 각각 5.8%와 1.5%로 소폭의 감소효과를 보였으나, 혼합물에서는 상기 두 성분의 산술평균 (3.2%)보다 훨씬 감소된 18.8% 감소하여 통계적으로 유의한 시너지 효과를 보였다. 90분에서는 홍삼과 금은화를 각각 투여 했을 때는 23.4%와 26.6%의 감소효과를 보였으나, 혼합물에서는 상기 두 성분의 산술평균 (25.0%)보다 월등히 감소된 37.8% 감소하여 통계적으로 유의한 시너지 효과를 보였다.In Figures 1 and 2, the sterling silver extract lowered the blood glucose concentration in a concentration-dependent manner. In particular, at 500 mg / kg, blood glucose levels decreased by 22.5% and 24.5% at 30 and 60 minutes, respectively. In addition, 100 mg / kg of the sample mixed with gold and silver ginseng extract and 1: 1 (weight ratio), respectively, and when administered red ginseng and gold and silver ginseng at 60 minutes, respectively, 5.8% and 1.5% respectively. Although there was a reduction effect, the mixture showed a statistically significant synergistic effect with a decrease of 18.8%, which is much lower than the arithmetic mean of the two components (3.2%). At 90 minutes, red ginseng and gold and silver were respectively decreased by 23.4% and 26.6%, but in the mixture, 37.8%, which was significantly lower than the arithmetic mean (25.0%) of the two components, was statistically significant. Seemed.
더욱이 120분에서는, 홍삼과 금은화를 각각 투여했을 때는 15.7%와 23.7%의 감소효과를 보였으나, 혼합물에서는 상기 두 성분의 산술평균 (19.7%)보다 현저히 감소된 45.5% 감소하여 통계적으로 유의한 시너지 효과를 보였다. 이러한 결과는 하기 표 2에 요약하였다.In addition, at 120 minutes, red ginseng and sterling silver were reduced by 15.7% and 23.7%, respectively, but in the mixture, a significant decrease of 45.5%, which was significantly lower than the arithmetic mean (19.7%), was statistically significant. It showed an effect. These results are summarized in Table 2 below.
[표 2] 대조군 대비 혈당 수치(%)[Table 2] Blood glucose level (%) compared to the control
*: P<0.05, **: P<0.01*: P <0.05, **: P <0.01
제조예 1. 금은화와 홍삼 추출물을 함유하는 음료Preparation Example 1 Drink Containing Gold Coin and Red Ginseng Extract
실시예 1과 2에서 제조된 금은화 추출물 1000mg과 홍삼 추출물 1000mg, 비타민C 75 mg, 비타민B2 4 mg, 비타민B6 3 mg, 식이섬유 1,000 mg, 액상과당 20000 mg, 유화제 100mg, 향료 50mg에 용량이 50 ml이 되도록 정제수를 혼합한다. 혼합액을 2∼3 ㎛의 필터를 통과시켜 청징화한 최종혼합액을 90∼93℃ 에서 15∼20초간 전 살균하여 50 ml병에 충진하고 80∼85℃에서 15∼20분간 후 살균하여 음료제품을 완성하였다.1000 mg gold and silver ginseng extract 1000 mg and red ginseng extract 75 mg, vitamin C 75 mg, vitamin B2 4 mg, vitamin B6 3 mg, dietary fiber 1,000 mg, liquid fructose 20000 mg,
제조예 2. 금은화와 홍삼 추출물을 함유하는 정제Preparation Example 2 Tablets Containing Gold Silver and Red Ginseng Extract
실시예 1과 2에서 제조된 금은화 추출물 1000 mg과 홍삼 추출물 1000 mg에 비타민C 75 mg, 비타민B2 4 mg, 비타민B6 3 mg, 식이섬유 100 mg를 혼합한 후 부형제로서 유당 200 mg, 락츄로스 260 mg과 향료 30 mg를 혼합하고 반죽하여 과립제조기를 통과시켜 과립을 제조한 다음 스테아린산 마그네슘 5 mg를 배합 하여 고르게 혼합한 뒤 일정한 중량으로 타정하여 정제제품을 완성하였다.1000 mg of gold and silver ginseng extract prepared in Examples 1 and 2 and 1000 mg of red ginseng extract were mixed with 75 mg of vitamin C, 4 mg of vitamin B2, 3 mg of vitamin B6, and 100 mg of dietary fiber, and then 200 mg of lactose and 260 mg of lactose as excipients. 30 mg of the fragrance was mixed and kneaded to prepare granules through a granulation machine. Then, 5 mg of magnesium stearate was mixed and evenly mixed, and then compressed into a certain weight to complete the tablet product.
이상 설명한 바와 같이, 본 발명에 따르면 금은화 추출물은 당 흡수를 효과적으로 억제하여 당뇨병에 효과적으로 사용될 수 있음을 알 수 있다. 특히 금은화 추출물과 홍삼 추출물의 혼합 조성물은 금은화 추출물과 홍삼 추출물을 각각 단독으로 투여하였을 때와 비교할 때 서로 상승효과가 있음을 확인하였다. 따라서 부작용이 없고 제 1형, 제 2형 당뇨병 모두에 사용가능하여 식?의약 산업에서 항 당뇨 소재로서의 이용이 증가할 것으로 판단된다.As described above, according to the present invention it can be seen that the gold silver extract can be effectively used for diabetes by inhibiting sugar absorption. In particular, it was confirmed that the mixed composition of the gold silver extract and red ginseng extract has a synergistic effect when compared with the administration of gold silver extract and red ginseng extract alone. Therefore, since there is no side effect and can be used for both type 1 and type 2 diabetes, the use as an antidiabetic material in the food and pharmaceutical industry is expected to increase.
도 1은 금은화 추출물에 따른 당내성 시험 결과이다.1 is a glucose tolerance test results according to the gold silver extract.
도 2는 금은화 추출물, 홍삼추출물 및 이들의 혼합물에 따른 당내성 시험 결과이다.Figure 2 is a glucose tolerance test results according to the gold silver extract, red ginseng extract and mixtures thereof.
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080050372A KR100979882B1 (en) | 2008-05-29 | 2008-05-29 | Compositions for preventing and curing diabetes comprising extracts of Lonicera japonica and Panax ginseng C.A. Meyer |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080050372A KR100979882B1 (en) | 2008-05-29 | 2008-05-29 | Compositions for preventing and curing diabetes comprising extracts of Lonicera japonica and Panax ginseng C.A. Meyer |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20090124268A KR20090124268A (en) | 2009-12-03 |
KR100979882B1 true KR100979882B1 (en) | 2010-09-02 |
Family
ID=41686217
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020080050372A KR100979882B1 (en) | 2008-05-29 | 2008-05-29 | Compositions for preventing and curing diabetes comprising extracts of Lonicera japonica and Panax ginseng C.A. Meyer |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100979882B1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TR201108485A2 (en) | 2011-08-23 | 2012-07-23 | Eraslan Mustafa | Extract combination of tribulus terrestris, avena sativa and panax ginseng. |
KR101683142B1 (en) * | 2014-06-09 | 2016-12-07 | 재단법인 진안홍삼연구소 | A pharmaceutical composition comprising extract of red ginseng and rubus coreanus for preventing, improving or treating diabetes mellitus |
WO2016013777A1 (en) * | 2014-07-21 | 2016-01-28 | 동국대학교 경주캠퍼스 산학협력단 | Composition for promoting anti-diabetic and anti-obesity effects, comprising herbal extract |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050005630A (en) * | 2003-07-07 | 2005-01-14 | 주식회사 엠디바이오알파 | Lonicera japonica extract having activity of enhancing IGF-1 secretion, its process method, and application |
-
2008
- 2008-05-29 KR KR1020080050372A patent/KR100979882B1/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050005630A (en) * | 2003-07-07 | 2005-01-14 | 주식회사 엠디바이오알파 | Lonicera japonica extract having activity of enhancing IGF-1 secretion, its process method, and application |
Non-Patent Citations (1)
Title |
---|
J. Ginseng Res., Vol.27, No.2, pp56-61 (2003.).* |
Also Published As
Publication number | Publication date |
---|---|
KR20090124268A (en) | 2009-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4133829B2 (en) | Carrot processing method | |
CN102271698A (en) | Pharmaceutical composition and use for preparing medicament thereof | |
JP2008528483A (en) | Mixed herbal medicine extract of 337 root, ripening yellow, and quince skin, and composition for preventing and treating arthritis comprising the same as an active ingredient | |
JP2011522844A (en) | Composition for reducing blood glucose level and use thereof | |
KR100784339B1 (en) | Anti-thrombus agent comprising extract of herbal mixture | |
EP2891496B1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING COMPLEX EXTRACT OF CRATAEGI FRUCTUS and CITRI PERICARPIUM AS AN ACTIVE INGREDIENT FOR TREATING OR PREVENTING OBESITY OR LIPID-RELATED METABOLIC DISEASES | |
CN104800608B (en) | A kind of herbal composite and its application with blood pressure reduction effect | |
KR100979882B1 (en) | Compositions for preventing and curing diabetes comprising extracts of Lonicera japonica and Panax ginseng C.A. Meyer | |
TWI678211B (en) | Uses of cistanche tubulosa extract and isoacteoside in protecting muscles | |
CN106581115B (en) | Composition containing yuankanin and ginseng and application thereof | |
KR101045025B1 (en) | Pharmaceutical composition for preventing or treatment of asthma | |
KR101910013B1 (en) | A composition for improving, preventing and treating of pain comprising herb extract | |
CN111135235A (en) | A composition for preventing and relieving acute alcoholism or alcoholic intoxication | |
KR101093730B1 (en) | Smilax china extracts compositions for treating or preventing inflammatory diseases | |
KR101119410B1 (en) | Foeniculum vulgar extracts compositions for treating or preventing inflammatory diseases | |
CN108902989A (en) | A kind of auxiliary improves the ginseng peptide and preparation method thereof of cardiovascular and cerebrovascular disease | |
KR20160066643A (en) | Anti-diabetic composition containing the extract of actinidia arguta leaves or fractions thereof | |
JP2004352626A (en) | Anticholesterol agent containing plant-derived component | |
CN100528186C (en) | Process for preparing Chinese medicine compound injection for treating chronic renal failure and use | |
KR100471340B1 (en) | A new process for enhancing the efficacies of Ginseng | |
KR100685472B1 (en) | Composition using vinegar processed ginseng preparation for treatment and prevention of type ? diabetes and metabolic syndrome | |
KR101119647B1 (en) | Torilis japonica extracts compositions for treating or preventing inflammatory diseases | |
CN111773315A (en) | Application of spiranthes sinensis extract in preparation of pharmaceutical composition for treating hypertension | |
KR101413771B1 (en) | A composition for anti-obesity comprising extract of big cone pine needle | |
JP2006193501A (en) | Adiponectin regulating agent and food, drink, food additive and medicine containing the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130722 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20140804 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20150723 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20160801 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20170728 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20190718 Year of fee payment: 10 |